Press Releases

Read about the latest Hoth Therapeutics
technology, research, investor updates
and much more.

Apr 20, 2021

Hoth Therapeutics Announces its mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell-Derived Cancers

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, announced that its novel anti-cancer therapeutic exhibited highly positive results in humanized...

Apr 12, 2021

Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial

Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully completed the formulation for HT-001, a...

Apr 6, 2021

Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced that it has engaged Worldwide Clinical Trials ("Worldwide"), a full-service Contract Research...

View All

Our Purpose

Founded in 2017, Hoth Therapeutics, Inc. was formed as a global platform to commercialize innovative and proprietary therapeutics. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders.

Home Page Icons